Benitec Biopharma
BNTC
13 hedge funds and large institutions have $6.58M invested in Benitec Biopharma in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
69% more capital invested
Capital invested by funds: $3.9M → $6.58M (+$2.68M)
2.27% more ownership
Funds ownership: 46.8% → 49.07% (+2.3%)
0% more funds holding
Funds holding: 13 → 13 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$246K |
| 2 |
GI
GAMMA Investing
Foster City,
California
|
+$12.3K |
| 3 |
Morgan Stanley
New York
|
+$6.14K |
| 4 |
Franklin Resources
San Mateo,
California
|
+$280 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.88K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$422 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Franklin Resources
San Mateo,
California
| $3.01M | +$280 | +73 | +0% |
|
|
2
Janus Henderson Group
London,
United Kingdom
| $1.27M | +$246K | +64,092 | +36% |
|
|
SCM
3
Suvretta Capital Management
New York
| $1.07M | – | – | – |
|
4
Adage Capital Partners
Boston,
Massachusetts
| $993K | – | – | – |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $87.7K | – | – | – |
|
|
6
Morgan Stanley
New York
| $62K | +$6.14K | +1,600 | +16% |
|
7
Geode Capital Management
Boston,
Massachusetts
| $51.3K | – | – | – |
|
|
GI
8
GAMMA Investing
Foster City,
California
| $18.7K | +$12.3K | +3,217 | +955% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $9.16K | -$2.88K | -750 | -30% |
|
|
10
UBS Group
Zurich,
Switzerland
| $2.69K | -$422 | -110 | -18% |
|
11
RhumbLine Advisers
Boston,
Massachusetts
| $952 | – | – | – |
|
12
Group One Trading
Chicago,
Illinois
| $456 | – | – | – |
|
13
Wells Fargo
San Francisco,
California
| $89 | – | – | – |
|
BNTC Hedge Fund Activity: Q1 2024 in Review
13 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2024, worth a combined $6.58M — up 69% from $3.9M a quarter earlier.
Fund positioning in BNTC was balanced in Q1 2024: 0 funds opened new positions, 0 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $246K. The largest seller was Tower Research Capital (TRC), cutting an estimated $2.88K.
- 13 institutional investors held Benitec Biopharma (BNTC) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $6.58M of Benitec Biopharma stock for Q1 2024, up 69% quarter-over-quarter.
- 0 funds opened new Benitec Biopharma positions in Q1 2024 and 0 closed out.
- The largest Benitec Biopharma buyer in Q1 2024 was Janus Henderson Group, an estimated $246K added.
- The largest Benitec Biopharma seller in Q1 2024 was Tower Research Capital (TRC), an estimated $2.88K sold.
Based on aggregated 13F filings for Q1 2024.